SCHEMBL2365633

SCHEMBL2365633

COC(=O)c1cccc(Sc2ccc(Cl)cn2)c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BRAF P15056 3/20 0.47
KDR P35968 3/20 0.47
RAB9A P51151 6/20 0.47
NPC1 O15118 5/20 0.47
MAPT P10636 4/20 0.47
ALDH1A1 P00352 3/20 0.45
HPGD P15428 3/20 0.45
NPSR1 Q6W5P4 2/20 0.45
L3MBTL1 Q9Y468 2/20 0.45
KDM4E B2RXH2 1/20 0.45
LMNA P02545 1/20 0.45
ATM Q13315 1/20 0.43
MEN1 O00255 2/20 0.41
KMT2A Q03164 2/20 0.41
MRGPRX4 Q96LA9 1/20 0.41
RECQL P46063 1/20 0.41
CDK8 P49336 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
KCNH2 Q12809 1/20 0.41
LOXL2 Q9Y4K0 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13366022 0.84 BRAF (0.61) BRAFKDRRAB9ANPC1ALDH1A1
SCHEMBL2365672 0.83 HPGD (0.51) BRAFKDRMAPTALDH1A1HPGD
SCHEMBL25249488 0.83 ALDH1A1 (0.52) BRAFKDRRAB9ANPC1MAPT
SCHEMBL30474744 0.83 ALDH1A1 (0.52) BRAFKDRRAB9ANPC1MAPT
SCHEMBL999887 0.81 RAB9A (0.51) RAB9ANPC1MAPTALDH1A1HPGD
SCHEMBL15227343 0.80 ALDH1A1 (0.47) RAB9ANPC1MAPTALDH1A1HPGD
SCHEMBL3696161 0.80 ALDH1A1 (0.49) RAB9ANPC1MAPTALDH1A1HPGD
SCHEMBL191866 0.77 ALDH1A1 (0.55) RAB9ANPC1MAPTALDH1A1HPGD
SCHEMBL15227150 0.77 MAPT (0.47) RAB9AMAPTL3MBTL1LMNAMEN1
SCHEMBL8806506 0.76 MAPK1 (0.54) RAB9ANPC1MAPTALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8927549-B2 Adamantyl benzamide derivatives HIGH POINT PHARMACEUTICALS, LLC (US) 2015-01-06 US disclosed
US-20110224244-A1 Adamantyl Benzamide Derivatives HIGH POINT PHARMACEUTICALS, LLC (US) 2011-09-15 US disclosed
EP-2362730-A1 ADAMANTYL BENZAMIDE COMPOUNDS High Point Pharmaceuticals, LLC (US) 2011-09-07 EP disclosed
WO-2010059618-A1 ADAMANTYL BENZAMIDE COMPOUNDS HIGH POINT PHARMACEUTICALS, LLC (US) 2010-05-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110224244-A1 Adamantyl Benzamide Derivatives HSD11B1, HSD17B11, HSD3B1 BRAF 4178/4885KDR 4238/4885RAB9A 2606/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.